The volume of research into new therapies for central nervous system (CNS) diseases is increasing to meet the needs of the increasing age of the global population.
Over the years, We have involved and managed many trials of CNS therapies, creating an extensive network of academic and private practice investigators in neurology, psychiatry, pain, sleep disorders and other neurological areas (i.e. image contrast agents).
We have also developed close relationships with international CNS experts / Key Opinion Leaders. This enables us to provide specialized related services such as management of the standardization of the evaluation of the cognitive function (rater reliability) or the expert management and central review of diagnostic images used in CNS research.
ProRelix Research’s CNS experience includes biopharmaceutical projects in stages from Phase II through Registry, performed both in adult and pediatric populations, in a broad range of indications, including but not limited to:
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Anxiety
- Depression
- Dementia
- Epilepsy
- Fibromyalgia
- Huntington’s chorea
- Insomnia
- Mild Cognitive Impairment
- Migraine
- Multiple Sclerosis
- Parkinson’s Disease
- Schizophrenia
- Sleep disorder
- Stroke
